AbbVie (ABBV) Stock Price & AI Analysis

$181.68
$4.24
(2.39%)
Biotechnology

NYSE USA

May 16, 5:47 PM EDT
  • Market Cap.
    320.92B
  • Volume
    12.07M
  • Avg. Volume
    8.10M
  • Target Price
    $214.88
  • 52W Range
    153.58 - 218.66
  • RSI (14)
    44.19
  • Beta
    0.48
  • PEG Ratio
    5.11
  • SMA 20
    -2.11%
  • SMA 50
    -6.48%
  • SMA 200
    -4.05%
  • Insider Owner
    0.11%
  • Insider Trans
    -12.62%
  • Institution Owner
    73.88%
  • Institution Trans
    0.21%
  • Short Interest
    19.8%
  • EPS next Y
    14.46

AbbVie Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson’s, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson’s, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

AbbVie | Latest news

Jim Cramer On AbbVie: Makes “Sense To Start a Position in the Stock”

Calling AbbVie Inc. (NYSE:ABBV) one of his “absolute favorites” during the recent episode of Mad...

Insider Monkey - 3 hours ago

Some May Be Optimistic About AbbVie's (NYSE:ABBV) Earnings

AbbVie Inc.'s (NYSE:ABBV) stock was strong despite it releasing a soft earnings report last week. We...

Simply Wall St - 4 hours ago

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should...

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is...

Zacks - 2 days ago

AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer

Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated...

Zacks - 1 day ago

Is AbbVie Inc. (ABBV) the Best Pharma Stock to Invest in Amid the Domestic...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now....

Insider Monkey - 3 days ago

AbbVie (NYSE:ABBV) Partners On siRNA Therapies And Earns Accelerated FDA...

AbbVie (NYSE:ABBV) has recently announced a significant collaboration with ADARx Pharmaceuticals,...

Simply Wall St - 1 day ago

Rep. Josh Gottheimer Sells Off Shares of AbbVie Inc. (NYSE:ABBV)

Representative Josh Gottheimer (D-New Jersey) recently sold shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on May 14th, the Representative disclosed that they had sold between $1,001 ...

ETF DAILY NEWS - 19 hours ago

AbbVie Inc. (ABBV): Among the Best Income Stocks to Invest in Now

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are...

Insider Monkey - 7 days ago

AbbVie Inc. (ABBV): Among the Best Dividend Growth Stocks with High Yields

We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this...

Insider Monkey - 2 days ago

Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals

The FDA granted approval to Merck’s MRK drug, Welireg, for its third indication in the United States...

Zacks - 10 hours ago